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Chromatin undergoes developmentally-regulated
structural and chemical changes as cells differentiate,
which subsequently lead to differences in cellular
function by altering patterns of gene expression. To
gain insight into chromatin alterations that occur dur-
ing mammalian differentiation, we turned to a mouse
embryonic stem cell (ESC) model. Here we show that
histone H3 is proteolytically cleaved at its N-terminus
during ESC differentiation. We map the sites of H3
cleavage and identify Cathepsin L as a protease re-
sponsible for proteolytically processing the N-termi-
nal H3 tail. In addition, our data suggest that H3 cleav-
age may be regulated by covalent modifications
present on the histone tail itself. Our studies under-
score the intriguing possibility that histone proteoly-
sis, brought about by Cathepsin L and potentially
other family members, plays a role in development
anddifferentiation thatwasnotpreviously recognized.
INTRODUCTION
Embryonic stem cells (ESCs) undergo dramatic changes in mor-
phology, cell cycle, and gene expression as they differentiate
into defined cell types (Kim et al., 2008; Murry and Keller,
2008). Since eukaryotic genomes are intimately associated
with histone proteins to form chromatin, this physiologically-
relevant structure must be remodeled as part of a large-scale
mechanism to achieve rapid and drastic changes in gene ex-
pression (Arney and Fisher, 2004; Gan et al., 2007). For example,
undifferentiated ESCs typically display increased physical plas-
ticity and less compacted chromatin than their differentiated
counterparts (Meshorer et al., 2006; Pajerowski et al., 2007).284 Cell 135, 284–294, October 17, 2008 ª2008 Elsevier Inc.ESCs also undergo radical changes in gene expression as they
differentiate, conveniently providing markers of ‘‘stemness’’
whose expression dramatically decreases (e.g., Oct 3/4) as
differentiation progresses. Such changes suggest that cells
undergo a significant reorganization of their genome during the
differentiation process and that, moreover, this transition must
be carefully regulated in order for the cell to differentiate properly
and adopt a specific lineage.
Recent studies have shown that histone covalent modification
patterns change significantly upon ESC differentiation (Giadrossi
et al., 2007). For example, core histones (H2A, H2B, H3, and H4)
are largely deacetylated upon differentiation and histone deace-
tylase activity may be required for ESC differentiation (Lee et al.,
2004). Chromatin-immunoprecipitation (ChIP) experiments have
also identified specific genes and/or genomic regions that
change their ‘‘epigenetic signature’’ upon differentiation (Azuara
et al., 2006; Bernstein et al., 2006a).
Despite a wealth of emerging data describing changing
patterns of epigenetic signatures during ESC differentiation,
very little is known about the mechanisms used to achieve
such change. Several possible mechanisms for removing the
more stable histone modifications, e.g., lysine methylation, in-
clude enzymatic demethylation, histone replacement, and regu-
lated histone proteolysis (Bannister and Kouzarides, 2004). En-
zymatic activities have been identified that carry out the first
two mechanisms (Ahmad and Henikoff, 2002; Shi et al., 2004)
and there is precedence for controlled histone H3-specific
proteolysis (Allis et al., 1980; Falk et al., 1990); however, to our
knowledge, specific, regulated, endogenous proteolysis has
not been well documented in mammalian cells.
Here, we show that ESCs employ regulated histone proteoly-
sis in order to change their ‘‘epigenetic signature’’ upon differen-
tiation. Furthermore, we have identified Cathepsin L as a devel-
opmentally-regulated histone H3 protease and demonstrated
that its activity may be modulated by the modification of the his-
tone tail itself. Taken together, our studies reveal unsuspected
Figure 1. A Distinct Histone H3 Species Is
Detected in Chromatin during ESC Differen-
tiation
(A) Undifferentiated (und) ESCswere differentiated
with RA in a monolayer, harvested for WCEs at the
time points indicated, and analyzed by immuno-
blotting with the antibodies indicated to the right
of each panel; H3gen refers to the H3 general
C-terminal antibody unless otherwise indicated.
Molecular weights (in kD) are indicated to the left
in all subsequent gels and immunoblots.
(B) Chromatin was isolated from undifferentiated
ESCs and ESCs differentiated with RA for
3 days, digested with micrococcal nuclease for
the indicated times, and analyzed by immunoblot-
ting; P = chromatin pellet input, P’ = post-Mnase
pellet.
(C) ESCs were differentiated using three basic
methods: monolayer differentiation with RA (left),
monolayer differentiation with LIF withdrawal
(middle), and embryoid body (EB) formation by
cell aggregation (right); WCEs were analyzed for
both a marker of pluripotency (Oct 3/4) and the
histone H3 sub-band (H3gen).nuclear functions of this family of cysteine proteases in histone
and stem cell biology and suggest that controlled histone prote-
olysis may be part of a mechanism for introducing variation into
the chromatin polymer.
RESULTS
A Faster Migrating H3 Species Is Detected
in Differentiating Mouse ESCs
To survey changes in histone proteins and their modifications
during mouse ESC differentiation, we used immunoblotting to
probe whole-cell extracts (WCEs) with various histone anti-
bodies. When probing with specific histone H3 antibodies
(e.g., the H3 general C-terminal, H3K27me2, and H3K27me1
antibodies), we observed reproducibly a faster migrating band
in samples taken at time points corresponding to days 2 and 3
postinduction with retinoic acid (RA). Notably, this band was
observed using an H3 general antibody generated against the
C terminus of histone H3 (Figure 1A and Figure S1 available
online), but not with an H3 general antibody generated against
the first six N-terminal amino acids (Figure S1). The faster migrat-
ing H3 species was also observed when probing immunoblots
with an H3-K27me2 antibody (Figure 1A); in contrast, it was
not recognized when replicate immunoblots were probed
with the H3-K4me3 antibody (Figure 1A). Taken together, the
results of these experiments suggested that an extreme amino-
terminal fragment of H3 was missing in the faster-migrating H3
sub-band.
We then asked if the H3 sub-band was chromatin associated.
Micrococcal-digested chromatin was prepared by standard
methods (Wysocka et al., 2001) from both undifferentiated
ESCs and ESCs undergoing differentiation with RA, and soluble
mononucleosomes were probed with the H3 general antibody.
As shown in Figure 1B, the faster migrating H3 band was seen
in the undigested chromatin pellet as well as in the solubilizedmononucleosomes derived from differentiating cells, but not
the chromatin isolated from undifferentiated ESCs (Figure 1B).
We next asked if the appearance of the faster migrating H3
species was dependent on the methods employed to trigger
ESC differentiation. To address this question, ESCs were differ-
entiated using three different methods: monolayer differentiation
with RA, monolayer differentiation by withdrawal of leukemic in-
hibitory factor (LIF), and embryoid body formation (EB formation)
by cell aggregation. As shown in Figure 1C (upper panels), the
time course for expression of pluripotency marker Oct3/4 differs
for each of the induction methods employed, suggesting differ-
ences in the timing and progression of differentiation. Timing of
the appearance of the faster migrating H3 band was also depen-
dent on the method used to induce ESC differentiation (lower
panels), suggesting that this event is also dependent on the
progress of differentiation. The faster migrating H3 was ob-
served at days 2 and 3 post-RA-induction during monolayer
differentiation (Figure 1A and Figure 1C, left), but delayed until
day 5 following withdrawal of LIF (Figure 1C, middle), the latter
correlating with the similarly delayed decrease of Oct3/4. During
EB formation, the faster migrating H3 species appeared early
and then peaked between days 8 and 12 (Figure 1C, right), sug-
gesting a slower and more complex differentiation progression.
We chose to use monolayer differentiation with RA for subse-
quent experiments in order to minimize differences in the timing
and heterogeneity of differentiation.
Histone H3, Marked by Both ‘‘Active’’ and ‘‘Silent’’
Modifications, Is Proteolytically Cleaved
in The N-terminal Tail during ESC Differentiation
To determine the nature of the faster migrating H3 sub-species,
histones were extracted from differentiating ESC nuclei 3 days
post-RA-induction and separated by reverse phase high pres-
sure liquid chromatography (RP-HPLC, C8 column, data not
shown). Fractions containing the H3 sub-band were pooledCell 135, 284–294, October 17, 2008 ª2008 Elsevier Inc. 285
Figure 2. Histone H3 Is N-Terminally
Cleaved during ESC Differentiation
(A) RP-HPLC fractions were screened for the H3
sub-band by immunoblotting (left). Equal amounts
of fractions 52–55 were then pooled, separated by
SDS-PAGE, and blotted to PVDF (middle). Each
sub-band (asteriks) was excised and subjected
to Edman degradation, which suggested that H3
had been N-terminally cleaved between residues
A21 and T22 and between K27 and S28 (right).
Residues not clearly identified in the generated
sequence are denoted ‘‘X.’’
(B) Sample in fraction 54 was digested with GluC
to generate intact, N-terminal peptides that termi-
nate with E50; peptides were then analyzed by
MS. Six highly modified, truncated fragments of
the GluC-generated 1–50 peptide were observed
(right). Note that the two sequences detected by
Edman degradation were also detected by MS
(asterisks). All six of the truncated 1–50 peptides
contain Ala at position 31 (underlined) and
are thus derived from the H3 isoform H3.2.
Three highly modified forms of the complementary
N-terminal fragments, A1-A21, A1-K23, and
A1-R26 (left) are also present in the same HPLC
fraction. n.d., not detected.
(C) The sequence of themammalian histone H3 tail
and the cleavage sites mapped in (A) and (B); the
bold solid line indicates the ‘‘primary’’ cleavage
site mapped by both Edman degradation and
MS (H3.cs1); additional significant cleavage sites are marked with regular solid lines; less abundant sites are marked by dashed lines. Lysines found by MS
to be highly acetylated (ac) or methylated (me) are marked by a triangle or circle, respectively (see Figure S2 for details).and further resolved byRP-HPLC (C18 column), and the resulting
fractions were screened by immunoblot as shown in Figure 2A
(left). We then subjected C18-RP-HPLC fractions containing the
H3 sub-band to two separate sequencing methods. First, equal
amounts of fractions 52–54 were pooled, separated by SDS-
PAGE, and transferred to immunoblot; the material in each of in
the two sub-bands labeled by asteriks was then subjected to Ed-
mandegradation (Figure 2A, right). Althoughmultiple aminoacids
were released during each cycle for both samples, the observed
data strongly suggested that the top and bottom sub-bands con-
tained sequences derived from cleavage following residues A21
and K27, respectively, in the N-terminal tail of H3.
Second, to define in greater detail the peptide sequences and
posttranslational modifications present in the faster migrating H3
species, additional sample from fraction 54 (Figure 2A) was
digested with GluC to produce N-terminal H3-fragments ending
in E50 and the resulting peptides were then analyzed by MS.
Spectra recorded detected six, highly-modified, truncated,
N-terminal, histone H3-peptides beginning at residues T22,
K23, A24, A25, K27, and S28 (Figure 2B, right). Relative abun-
dances of the six peptides suggest that the preferred cleavage
sites are C-terminal to A21 and K23. These results suggest
that the primary H3 cleavage site is between amino acids 21
and 22 of the amino terminus (Figure 2C, H3.cs1) and that the
final cleavage site is between amino acids 27 and 28. Notably,
the list of cleavage sites detected by MS contains the two sites
detected by Edman degradation (asterisks).
In addition, new mass spectrometric methods using a combi-
nation of electron transfer dissociation/proton transfer charge286 Cell 135, 284–294, October 17, 2008 ª2008 Elsevier Inc.reduction and accurate mass measurements were employed
to characterize the modification patterns on the proteolyically
cleaved H3 (Coon et al., 2005; Taverna et al., 2007). Interestingly,
the data reveal that the cleaved H3 subspecies has a distinct
covalent modification profile, suggesting that the H3 sub-band
may be preferentially marked, before or after proteolytic pro-
cessing, with a specific epigenetic signature (Figures 2C and
S2). Specifically, marks of both ‘‘active’’ (e.g., H3K23Ac and
H3K36me) and ‘‘silent’’ transcription (e.g., H3K27me) were
reproducibly detected on a single GluC-digested peptide de-
rived from the proteolytically processed H3 fragment. Moreover,
all six of the truncated peptides contained Ala at position 31, re-
vealing that the cleaved H3 peptide is H3 isoform H3.2, not H3.3.
Although noncleaved H3.3 peptide was detected in the same
RP-HPLC fraction as the cleaved H3 species, cleaved H3.3
was not detected. Since H3.2 and H3.1 elute in two separate
peaks, we cannot definitively conclude that H3.2 is preferentially
cleaved over H3.1, however significantly less H3 cleavage was
detected in peak 2 (H3.1) than in peak 1 (H3.2 + H3.3) by
immunoblotting. Although it is unclear how this particular pattern
of modifications and H3 isoform affect the mechanism of
proteolysis, these data suggest the intriguing possibility that
that regulation via posttranslational modification of the substrate
and/or isoform preference may regulate the proteolytic process-
ing (see Figure 7).
Also detected in fraction 54 (Figure 2A) were highly modified
forms for three of the most abundant, complementary, N-termi-
nal fragments generated by proteolytic cleavage of H3 (Fig-
ure 2B, left). The detection of these intact, complementary
Figure 3. The Cysteine Protease Cathepsin
L Is Detected in Fractions Enriched for
Histone H3 Cleavage Activity
(A) Schematic of in vitro H3 cleavage assay (see
text for details).
(B) A representative example of the H3 cleavage
assay comparing soluble cytosolic + nuclear pro-
tein extract (S) and solubilized chromatin extract
(C) from undifferentiated ESCs to those prepared
from 3 days + RA differentiating ESCs.
(C) Schematic of extract fractionation for protease
enrichment.
(D) H3 cleavage assay of hydroxyapatite fractions
generated by scheme shown in (C); assay reac-
tions were analyzed by immunoblotting with both
HIS-HRP and H3.cs1 antibodies.
(E) Hydroxyapatite fractions assayed in (D) were
analyzed for the presence of Cathepsin L by im-
munoblotting with Cathepsin L antibody; # desig-
nates proprotein (37 kD),  indicates intermedi-
ate processed form (30 kD), and * indicates
mature processed form (25 kD).cleavage products indicates that the cleavage sites mapped
above are the result of endopeptidase activity alone. Posttrans-
lational modifications detected on these three N-terminal pep-
tides again include marks of both ‘‘active’’ (e.g., H3K14Ac) and
‘‘silent’’ transcription (e.g., H3K9me) as seen on the C-terminal
fragments (Figure S2). These findings support the conclusion
that a small fraction of total histone H3.2 undergoes highly spe-
cific endoproteolytic cleavage during ESC differentiation that
may be regulated by unique patterns of covalent modifications.
The Lysosomal Cysteine Protease Cathepsin
L is Present in Fractions that Are Enriched
with H3 Protease Activity
To identify and characterize the putative H3 protease(s), we first
established an in vitro H3 cleavage assay. Undifferentiated or
differentiating ESCswere harvested and their proteins extracted;
these lysates were then incubated with C-terminally 6xHIS
tagged, full-length recombinant histone H3 (rH3-HIS), and the re-
action products were analyzed by immunoblotting with HIS-HRP
antibody (Figure 3A). Although this assay has the potential to
detect any N-terminal H3 cleavage, chromatin isolated from
differentiating ESCs at the time point when in vivo cleavage
was observed (3 days + RA) consistently possessed strong
in vitro H3 cleavage activity that reproduced the size difference
of the endogenously cleaved H3 (Figure 3B).
To better ensure that the cleaved H3 product observed in our
in vitro cleavage assay was physiologically relevant, we gener-
ated an antibody that recognized the primary site of H3 cleavage,
H3.cs1 (Figure 2C; see Experimental Procedures and Figure S4
for details on antibody generation and characterization). Our re-
sults indicated that this antibody (‘‘H3.cs1’’) was specific for the
primary site of in vivo generated H3 cleavage product (A21/T22)
and was not sensitive to the acetylation status of H3K23 (see
characterization by ELISA and immunoblotting in Figure S4). Im-portantly, the H3.cs1 antibody fails to react with full length H3
and its signal is highly enriched at the same time point at which
we detect an H3 sub-band using the H3-general or H3 K27me2
antibodies during our standard RA-induced ESC differentiation
time course (Figure S4B).
We then used both the HIS-HRP antibody and the H3.cs1 an-
tibody in the above H3 cleavage assay to follow the biochemical
enrichment of H3 protease activity in nuclear extract derived
from differentiating ESCs. We fractionated nuclear extract
(Figure 3C) and detected two peaks of putative H3 cleavage ac-
tivity by both the HIS-HRP antibody and the H3.cs1 antibody
(Figure 3D). We then subjected two activity-containing fractions
(#22 and 23, Figure 3D) and an adjacent nonactivity-containing
fraction (#20) to MS analysis. Four peptides were detected for
the cysteine protease Cathepsin L in both activity-containing
fractions 22 and 23, yet none of these peptides were detected
in the neighboring nonactivity containing fraction 20 (Figure S5
for details). To validate this identification further, we used a
commercially available antibody to screen for the presence of
Cathepsin L in the hydroxyapatite fractions (mCathL, Figure 3E).
Importantly, reactivity with mCathL correlates well with the de-
tection of H3 cleavage activity in the fractions aligned above
(compare Figure 3D to 3E).
Cathepsin L is known to exist in three forms: a proenzyme run-
ning at37 kD, a single chain intermediate at30 kD, and a dou-
ble chain mature form at25 kD and5 kD (Ishidoh et al., 1998).
The pro formmust be cleaved to become active, whether by self-
cleavage or by another enzyme (Turk et al., 2000); in contrast,
both the ‘‘intermediate’’ and ‘‘mature’’ forms have been shown
to be active (Mason et al., 1989). The hydroxyapatite fractions
of the stronger peak of activity (21–25) correlate with the detec-
tion of the mature form of Cathepsin L by immunoblot (Figure 3E,
marked by asterisk), while the weaker activity fractions (13–15)
correlate closely with the detection of the intermediate form ofCell 135, 284–294, October 17, 2008 ª2008 Elsevier Inc. 287
Figure 4. Cathepsin L Cleaves Histone H3 In
Vitro and Associates with Chromatin In Vivo
(A) Hydroxyapatite fraction #23 (Figure 3D) was
assayed +/ protease inhibitors in the H3 cleav-
age assay; cysteine protease inhibitor E64 is a
potent inhibitor of the H3 protease activity in
fraction #23.
(B) Immobilized E64 was incubated with both an
active hydroxyapatite fraction (23) and onewithout
enzymatic activity (20); control resin was incu-
bated with each fraction in parallel. Resins were
then analyzed for bound proteins by immunoblot-
ting (bottom panel) and the supernatant was
tested for H3 protease activity (top panel).
(C) Hydroxyapatite fraction #23 (Figure 3D) was
assayed with various rH3-HIS point mutants in
the H3 cleavage assay.
(D) Chromatin from undifferentiated ESCs and
ESCs differentiated + RA for the number of days
indicated was digested with micrococcal nucle-
ase; the solubilized mononucleosomes were
analyzed by immunoblotting with Cathepsin L
antibody.Cathepsin L (Figure 3E, marked by dot). This correlation not only
supports a causal relationship between the presence of Cathep-
sin Land theH3cleavageactivity, but alsohelps toexplain thedif-
ference in elution and activity between the twopeaks ofH3 cleav-
age activity generated by the hydroxyapatite chromatography.
Fractions Enriched in H3 Cleavage Activity Exhibit
Cathepsin L-like Activity
To validate further the identification of Cathepsin L as a histone
H3 protease, we tested our enriched fractions with different clas-
ses of protease inhibitors in our H3 cleavage assay. As shown in
Figure 4A, adding increasing amounts of serine protease inhibi-
tor AEBSF produced a modest reduction in cleavage activity at
a high concentration (20 mM), but not at the lower concentra-
tions tested (2 mM and 10 mM). However, when using the cyste-
ine protease inhibitor E64, all cleavage was abolished at even the
lowest concentration tested (10 mM).
Noting the strong inhibition of H3 cleavage activity by E64, an
irreversible inhibitor that binds covalently to its substrate and has
been shown to inhibit Cathepsin L (see Figure S6 and Barrett
et al., 1982), we then took advantage of a commercially available
E64-bound resin to test whether it could precipitate Cathepsin
L from our active hydroxyapatite fractions and, subsequently,
remove the soluble H3 cleavage activity. Both E64 bound and
control resins were added to fractions 20 (in which little to no
H3 cleavage activity detected) and 23 (in which strong H3 cleav-
age activity was detected), incubated to allow binding and po-
tential inhibition, and then pelleted by centrifugation. The cleared
supernatant was subsequently tested for H3 cleavage activity.
As expected, E64 resin successfully removed H3 cleavage activ-
ity from fraction 23, while control resin did not (Figure 4B, top).
Importantly, as shown using the cleavage-site specific H3.cs1
antibody, the activity removed by the E64 resin included the
specific A21/T22 cleavage site activity.
We then eluted any bound proteins from the E64 and control
resins and probed the eluates for the presence of Cathepsin L.288 Cell 135, 284–294, October 17, 2008 ª2008 Elsevier Inc.As hypothesized, mCathL was detected on the +E64 resin that
had been incubated with fraction 23, but not on control resin
nor on resin incubated with fraction 20 (Figure 4B, bottom). As
a control, we also analyzed the above eluates by immunoblotting
with an antibody to another cathepsin family member, Cathepsin
B, but did not detect any immunoreactive species (data not
shown). Taken together, the loss of activity from solution paired
with the presence of Cathepsin L protein bound to the corre-
sponding +E64 resin strongly suggests a causal relationship
between this cysteine protease and the primary H3 protease
activity characterized above (H3.cs1).
Cathepsin L is also known to preferentially cleave proteins that
contain hydrophobic residues in their P2 position (two residues
N-terminal fromthecleavedbond,asoriginallydefined (Schechter
and Berger, 1967)), specifically leucine and phenylalanine (Raw-
lings and Barrett, 2007; Rawlings et al., 2008). Importantly, and
in keeping with this characteristic, the sequence surrounding the
primary H3 cleavage site (A21/T22) mapped from ES cells by
both MS and Edman degradation (Figure 2C, solid line) includes
a leucine at the P2 position (L20). To verify the significance of
this leucine in the H3 sequence and support the identification of
Cathepsin L in fraction 23, we mutated it (L20V, L20E & L20W)
as well as neighboring residues and tested the mutated recombi-
nant proteins in our H3 cleavage assay (Figure 4C). Although the
more conservative L20Vmutant showed little change in H3 cleav-
age, L20E and L20Wmutants completely abolished H3 cleavage
as assayed by both the HIS and H3.cs1 antibodies (top panels).
Moreover, the loss of H3 cleavage upon mutation of L20, com-
pared to little or no lossof signal uponmutationof neighboring res-
idues (K18 or A21), suggests that L20 is particularly important to
the enzymatic activity in fraction 23. Together, this mutational
analysis also supports the identification of Cathepsin L as the
enzyme responsible for the histone H3 cleavage characterized
in the above in vitro assays.
Interestingly, mutating K23 to either S or Q also had a signifi-
cant effect on the H3 cleavage activity (Figure 4C, bottom
Figure 5. Cathepsin L Cleaves Histone H3
In Vitro
(A) Recombinant Cathepsin L cleaves rH3 in vitro
at both pH 5.5 and pH 7.5 and generates a frag-
ment that is recognized by both a-HIS-HRP (top
panel) and a-H3.cs1 (middle panel) antibodies.
(B) Recombinant mouse Cathepsin L was incu-
bated with recombinant H3-HIS at both pH 5.5
and pH 7.5; after 2 hr, the reaction products
were subjected to analysis by mass spectrometry.
Both N-terminal (left) and C-terminal (right) frag-
ments of the rH3 cleavage were detected; note
the similarity to the pattern of in vivo cleavage
shown in Figure 2B. n.d., dnot detected.
(C) Recombinant Cathepsins B, K, and L were pre-
activated and incubated with recombinant H3-HIS
at both pH 5.5 and pH 7.5 for 15 min; the reactions
were separated by SDS-PAGE and analyzed by
immunoblotting.panels). Although no difference was seen in H3 cleavage by as-
sayingwith HIS, thesemutations greatly diminished the cleavage
site recognized by the H3.cs1 antibody, suggesting a possible
role for this residue in regulating the precision of H3 proteolysis
by Cathepsin L. It is interesting to note that none of the N-termi-
nal peptides identified by MS were acetylated at K23 while
C-terminal peptides acetylated at K23 were consistently de-
tected (Figure S2). Together, these data suggest the intriguing
possibility that the acetylation of K23 may serve to inhibit cleav-
age at certain sites.
Cathepsin L Is Associated with Chromatin In Vivo
Although there is previousevidence thatCathepsinL and its activ-
ity exists in the cell nucleus of MEFs (Goulet et al., 2004), we set
out to document this nuclear localization in ESCs using a bio-
chemical approach: we isolated chromatin and then solubilized
it by micrococcal nuclease digestion as described above (Fig-
ure1C). As shownbyproblingwithCathepsin L antibody,Cathep-
sin L was indeed associated with chromatin fragments released
by nuclease digestion (Figure 4D). Importantly, chromatin associ-
ation only begins to appear upon differentiation and is not appar-
ent in undifferentiated ES cells. We note as well that the mature
form of Cathepsin L (marked by asterisk) was enriched over the
full length (hash) or intermediate (dot) forms.
rCathepsin L Reproduces the In Vivo Histone H3
Cleavage Pattern
To further validate the identification of Cathepsin L as an H3 pro-
tease, we tested recombinant mouse Cathepsin L enzyme in our
H3 cleavage assay (Figure 5). Since Cathepsin L displays optimal
activity at the more acidic pH of the lysosome (i.e., pH 5, (Bar-
rett et al., 2003)), and since we suspected that Cathepsin L is
acting within the nucleus at a higher pH (pH 7–8), we tested
the recombinant enzyme in both pH environments. Importantly,
recombinant mouse Cathepsin L was able to cleave recombi-
nant histone H3 at both pH 5.5 and pH 7.5. Moreover, the re-combinant enzyme cleaved H3 and created the specific epitope
recognized by the cleavage site-specific H3.cs1 antibody
(Figure 5A). To further characterize the sites of proteolytic cleav-
age, we analyzed the reaction products of rCathepsin L and rH3-
HIS byMS. Importantly, MS analysis revealed that the six sites of
cleavagemapped in the endogenous H3 samples (Figure 2) were
also produced by rCathepsin L in vitro (Figure 5B). Summed ion
currents for all charge states of the unmodified sequences were
employed to estimate the relative abundances of the six pep-
tides beginning with the indicated residues as follows: T22 >
K23, A24, and S28 > A25 and K27. The most abundant site of
cleavage in vitro was between A21 and T22, the same site that
was shown to be most abundant in the MS analysis of endoge-
nous histone H3. In addition, the relative abundances of the
in vivo H3 cleavage sites and those produced by Cathepsin L
in vitro are highly correlative. One exception is cleavage between
residues K27 and S28, which is more abundant in the in vitro as-
say compared to that mapped from in vivo samples (the latter
shows a preference for cleavage between residues R26/K27
over K27/S28). We speculate that the presence of histone mod-
ifications in vivo play a role in regulating the preferred cleavage
site of Cathepsin L, particularly at sites surrounding H3K27,
which was shown to be preferentially methylated on cleaved
H3 by both immunoblot and MS analysis (Figures 1A and S2).
Also observed in both reactions are five of the six complemen-
tary N-terminal peptides generated by rCathepsin L cleavage
of H3 (left), and their abundances correlated with that of their
C-terminal counterparts. Taken together, the above data sup-
port the conclusion that Cathepsin L is capable of generating
all of the histone H3.2 fragments observed at day 3 following
induction of ESC differentiation by retinoic acid.
We then wanted to test other cathepsin family members in the
H3 cleavage assay. We chose to test rCathepsin B, one of the
most abundant lysosomal proteases, and rCathepsin K, which
is reported to have a significant preference for leucine in the
P2 position of its substrates much like Cathepsin L (CathepsinCell 135, 284–294, October 17, 2008 ª2008 Elsevier Inc. 289
Figure 6. Both RNAi and Chemical inhibi-
tion of Cathepsin L Reduce Histone H3
Cleavage In Vivo
(A) Control and CathL RNAi cells lines were differ-
entiated with RA as usual and harvested at the
indicated time points; WCEs were then separated
by SDS-PAGE and analyzed for both Cathepsin L
expression (upper panel) and histone H3 cleavage
(lower panel) by immunoblotting.
(B) A serial two-fold dilution of samples from day 3
postinduction with RA were resolved by SDS-
PAGE gel and analyzed by immunoblotting as
in (A).
(C) The addition of Cathepsin L Inhibitor I to the cell
media of differentiating ESCs (left side) inhibits the
processing of Cathepsin L itself (a) as well as that
of histone H3 (b, c) as compared to DMSO alone
treated control cells (right side). Loss of pluripo-
tency marker Oct 3/4 was not affected (d) nor
was the self-processing of another cathepsin
family member, Cathepsin B (e).S also shares this preference but was not found to have signifi-
cant expression in our ESC model). Following preactivation,
the recombinant enzymes Cathepsins B, K, and L were incu-
bated with rH3-HIS at both pH 5.5. and pH 7.5, and the reactions
were then analyzed by immunoblotting with both HIS and H3.cs1
antibodies. As shown in Figure 5C, pre-activated Cathepsin L
cleaves rH3-HIS robustly and produces a pattern that is similar
to that observed in vivo. In contrast, Cathepsin B cleaves rH3
with a distinct pattern from Cathepsins K or L and does not sig-
nificantly produce the H3.cs1 epitope. Cathepsin K produces
a similar pattern to Cathepsin L under these assay conditions,
although they appear to differ in their preferences for specific
sites (e.g., the cleavage site recognized by the H3cs.1 antibody
is less abundant in the Cathepsin K reactions).
Both RNAi-mediated and Chemical Inhibition
of Cathepsin L Inhibits H3 Cleavage In Vivo
We then sought to show that knockdown of Cathepsin L in vivo
led to a decrease in H3 cleavage. Stable cells lines constitutively
expressing short RNAi hairpins to a control gene and theCathep-
sin L gene (Ctsl) were differentiated with RA, as usual, and cells
were harvested at various time points. In parallel, samples taken
at day 3 postinduction with RA were also evaluated for knock-
down efficiency and H3 cleavage by titration of sample (Fig-
ure 6B). As shown in Figures 6A and 6B, knockdown of Cathep-
sin L (shown by immunoblotting with Cathepsin L antibody,
upper panels) led to reproducible decrease in H3 cleavage as
detected by the H3 C-terminal antibody (lower panels).
To further assess whether Cathepsin L causes histone H3
cleavage in vivo, we chose to use a commercially available,
cell-permeable Cathepsin L specific inhibitor, Cathepsin L Inhib-
itor I. Inhibition of Cathepsin L using a chemical inhibitor allowed
us to assess the effect of Cathepsin L inhibition within a single,
wild-type cell line rather than comparing individual cell lines cre-
ated by drug selection. Undifferentiated ESCs were treated with
or without inhibitor for 24 hr prior to plating for differentiation.
Cells were then differentiated with RA while either Cathepsin L290 Cell 135, 284–294, October 17, 2008 ª2008 Elsevier Inc.Inhibitor I (10 mM) or DMSO alone was maintained in the media.
As shown in Figure 6C, cells treated with inhibitor showed signif-
icant failure to fully process Cathepsin L from its intermediate
form (marked by dot) into its mature form (asterisk), demonstrat-
ing that its activity had been inhibited (Figure 6C, panel a, left). In
contrast, no significant accumulation of the intermediate form
was seen in the DMSO alone treated cells (right). Notably, his-
tone H3 cleavage also decreased significantly in the cells treated
with the inhibitor, but not in cells treated with DMSO alone, as
shown by probing immunoblots with both H3-general and
H3.cs1 antibodies (Figure 6C, panels b and c). Interestingly, all
cleavage detected by the H3-general antibody was abolished
in the cells treated with inhibitor, suggesting that Cathepsin L
is responsible for all sites of cleavage (supported by MS data
in Figure 5).
Importantly, neither Oct-3/4 nor Cathepsin B levels (Figure 6C,
panels d and e) appeared to change upon addition of the inhib-
itor. Since Oct-3/4 is a marker of pluripotency that is normally
lost rapidly upon differentiation with RA (Figure 1C), the fact
that this pattern is unchanged in the presence of the Cathepsin
L Inhibitor I indicates that the inhibitor does not alter the pluripo-
tency or differentiation capacity of ESCs prior to the time point at
which H3 cleavage is observed. The consistency of Cathepsin B
levels between those cells treated with Cathepsin L Inhibitor I
and control cells suggests that the inhibitor is indeed specific
for Cathepsin L.
Histone Tail Modifications Can Modulate Cathepsin
L Activity and Its Downstream Effects
We then asked whether known covalent modifications on the
histone tail affect the cleavage activity of Cathepsin L. As de-
picted in Figure 2C, several amino acids near the sites of Cathep-
sin L cleavage are known to be modified by either acetylation
(triangles) or methylation (circles). To test the potential effects
of these modifications on the cleavage activity of Cathepsin L,
we first turned to the H3 cleavage assay described in Figure 3.
Four different recombinant H3 substrates were prepared as
Figure 7. Covalent Histone Modifications Modulate Cathepsin L Activity and Its Downstream Effects
(A) rCathepsin L was incubated with each of four rH3 substrates: 1 = rH3 unmodified, 2 = rH3 alkylated to K27me2, 3 = rH3 pan-acetylated with acetic anhydride,
4 = rH3+K27me2 pan-acetylated with acetic anhydride.
(B) H3 cleavage reactions were performed as in (A) using synthesized peptides that represent the H3 tail from amino acids 15–31. Reactions were incubated
with 250pmol peptide and quenched with 0.1% TFA before being plated in duplicate for ELISA with the H3cs.1 antibody. Signal was normalized to that of
mock reactions for each peptide. Results represent the mean of three independent experiments ± SD.
(C) Peptide pull-down assays were performed with recombinant mouse CBX7-chromodomain or rhBPTF-PHD finger and H3 peptides (sequences and methyl-
ation states indicated). Peptide-bound polypeptides were resolved by SDS PAGE and visualized by silver staining.
(D) Fluorescence anisotropy of Cbx7-CD protein binding to noncleaved peptide (18–37) versus cleaved peptide (22–37); binding decreases 3-fold with cleaved
peptide, p < 0.01. Kds are in mM ± SEM. Data points represent the mean ± SD.follows: unmodified rH3, rH3 dimethylated specifically at
K27me2, rH3 ‘‘pan-acetylated’’ by treatment with acetic anhy-
dride and rH3 with both K27me2 and pan-acetylation. These
substrates were shown to have the specific modifications of
interest by immunoblot (Figure S7) and were verified by MS
(R90%, data not shown). As shown in Figure 7A, this assay dem-
onstrated that acetylation of lysine residues greatly reduced
cleavage of H3 by rCathepsin L at both pH 7.5 and pH 5.5 (com-
pare substrate 1 with 3). In contrast, K27me2 increases H3
cleavage (compare substrate 1 to 2; greater depletion of full-
length rH3+K27me2 suggesting increased cleavage activity at
pH 5.5).
In order to test the effect of these modifications more quanti-
tatively and specifically, we synthesized a set of five peptides
with identical backbone sequence flanking the H3 cleavage
site (H3 15–31) modified as follows: unmodified, K18 acetyl,
K23 acetyl, K18ac+K23ac, and K27me2. We then employed an
ELISA based assay using the H3cs.1 antibody to quantitatively
measure the H3cs.1 cleavage activity of rCathepsin L on these
peptides. As shown in Figure 7B, clear differences in rCathepsin
L activity were observed at both pH 7.5 and pH 5.5. As sug-
gested by the rH3 cleavage assay described above, K27me2(magenta) strongly increases the ability of Cathepsin L to cleave
at H3cs.1 as compared to the matched unmodified H3 15–31
peptide (red). Interestingly, acetylation at K18 (blue) also in-
creases this activity, suggesting that the acetylation of another
lysine(s) must be responsible for the abrogation of cleavage by
acetylation demonstrated above. Our data suggest that acetyla-
tion at K23ac is at least partly responsible for this effect, as the
K23ac peptide shows very little cleavage activity at H3cs.1,
both alone (green) and in combination with K18ac (black).
We then asked what effect of the cleavage of the H3 tail might
have on the binding of effector proteins. Since K27methylation is
a well-documented binding site for the chromodomain-contain-
ing protein Polycomb (Bernstein et al., 2006b; Fischle et al.,
2003), we sought to test the effect of H3 cleavage on Pc binding
to H3K27 methylation. Using peptides that mimicked either the
‘‘noncleaved’’ H3 tail (H3 18–37) or the ‘‘cleaved’’ H3 tail (H3
22–37), we assayed the effects of H3 cleavage on the ability
for the chromodomain of mouse Pc (CBX7-CD) to bind to K27
methylation (Figure 7C); the PHD-finger of the known H3K4
methyl binding protein BPTF was used as a positive control
and to demonstrate specificity. As shown in Figure 7C and quan-
tified in 7D, H3 cleavage significantly diminished the ability ofCell 135, 284–294, October 17, 2008 ª2008 Elsevier Inc. 291
CBX7 to bind to H3K27 methylation, suggesting that proteolytic
modification introduced by Cathepsin L could lead to significant
downstream effects.
DISCUSSION
A rapidly growing literature demonstrates that cells undergo dra-
matic developmentally-regulated changes in gene expression
and cellular morphology upon transition from undifferentiated
stem cells to specific lineages (Giadrossi et al., 2007; Kim
et al., 2008; Murry and Keller, 2008). Despite remarkable prog-
ress made in documenting epigenetic signatures such as ‘‘biva-
lent domains’’ i.e., an H3 tail bearing both H3K4me3 and
H3K27me3 marks (Bernstein et al., 2006a), little is known as to
what mechanisms may function to bring about the above
changes at a chromatin level. Our data suggest that mouse
ESCs employ a regulated histone H3 proteolysis mechanism
thatmay serve to alter epigenetic signatures upon differentiation.
Other means of actively removing histone methyl marks have
been well documented, including enzymatic demethylation
(Anand and Marmorstein, 2007; Shi et al., 2004) and selective
histone variant replacement (Ahmad and Henikoff, 2002). How-
ever, considerably less evidence documenting endogenous his-
tone proteolysis has been reported (Allis et al., 1980; Falk et al.,
1990). The identification and characterization of developmen-
tally-regulated H3 cleavage by Cathepsin L during ESC differen-
tiation is an important step in understanding limited nuclear his-
tone proteolysis as a potential mode of transcriptional regulation.
Our finding that Cathepsin L cleaves histone H3 in mouse ES
cells was unexpected as this enzyme was originally described
as a lysosomal protease (Barrett et al., 2003). However, Cathep-
sin L has been shown to localize to nuclei where it plays a role in
the proteolytic processing of transcription factor CDP/Cux (Gou-
let et al., 2004); biochemical studies have also shown that pro-
Cathepsin L is localized to the nucleus in ras-transformedmouse
fibroblasts (Hiwasa and Sakiyama, 1996). In addition, evidence
of endogenous, nuclear serpin inhibitors with the ability to inhibit
Cathepsin L activity, e.g., MENT (Bulynko et al., 2006) and
Cystatin B (Riccio et al., 2001), further supports the notion that
Cathepsin L, and potentially other cysteine proteases, play im-
portant but poorly understood roles in regulated nuclear proteol-
ysis. As far as we are aware, transcription factor CDP/Cux is the
only nuclear substrate of Cathepsin L identified to date, and his-
tones have not yet been identified as substrates of this class of
proteases in mammalian cells. Interestingly, however, recent
studies in sea urchin have suggested that a Cathepsin L-like cys-
teine protease may be responsible for the degradation of sperm
histones during a key chromatin remodeling event after fertliza-
tion (Morin et al., 2008). Our data support other studies that dem-
onstrate the nuclear localization of Cathepsin L and provide the
first indication that cellular histones, H3 in particular, are key sub-
strates of this family of proteases in mammalian cells.
Our finding that Cathepsin L is an H3 protease is interesting
when considering the phenotype common to the Cathepsin L
knockout mouse (Nakagawa et al., 1998) and the Cathepsin L
mutant mouse, furless (Roth et al., 2000). These mice exhibit pe-
riodic hair loss due to the improper cycling and morphogenesis
of their hair follicles, suggesting a defect in stem cell renewal292 Cell 135, 284–294, October 17, 2008 ª2008 Elsevier Inc.and/or differentiation. Cathepsin L knockout mice are viable
and fertile, however, indicating that its functions are nonessential
and/or redundant. Interestingly, Cathepsin L/Cathepsin B dou-
ble knockout mice exhibit severe brain atrophy and die two to
four weeks after birth (Felbor et al., 2002). The severity and selec-
tivity of this phenotype suggests that these two enzymes overlap
in their specific functions. Althoughwe do not observe significant
inhibition of Cathepsin B upon in vivo chemical inhibition of Ca-
thepsin L, nor do we observe the same pattern of H3 cleavage
with recombinant Cathepsin B compared to Cathepsin L
in vitro, we cannot exclude the possibility that redundancy in
H3 cleavage function may exist between these or other related
enzymes at other stages or lineages of differentiation.
Limited proteolysis of nuclear proteins is an important means
of regulating transcription and other cell processes (Goulet and
Nepveu, 2004; Vogel and Kristie, 2006). Here we show that lim-
ited proteolysis of histone H3 by Cathepsin L occurs during the
differentiation of ESCs and may be regulated both positively
and negatively by covalent modifications on the H3 tail itself.
These findings require a revaluation as to the function of this fam-
ily of enzymes in transcriptional and epigenetic regulation; many
important questions remain. First, how is the protease cleavage
activity regulated? Along this line, we show that covalent modi-
fications (such as acetylation and/or methylation of nearby
lysines) serve to regulate, positively and negatively, the H3 pro-
teolytic processing event. We note that proteolytic processing
of H3 in the ciliate model occurs selectively in a hypoacetylated,
transcriptionally silent (micronuclear) genome, while processing
of H3 fails to occur in hyperacetylated, transcriptionally active
macronuclei (Allis et al., 1980). These data raise the question
as to whether other chromatin-modifying enzyme complexes,
such as HATs, HDACs, or ubiquitinating enzymes, play a role
in regulating histone proteolysis.
Second, by what mechanism is the cleaved H3 replaced, and
is DNA replication and chromatin assembly required? Our
findings that the histone variant H3.2 is preferably cleaved as
compared to H3.3 suggests that S-phase/replication-coupled
replacement may be involved (Loyola and Almouzni, 2007).
Along this line, we note that proteolytic processing of transcrip-
tion factor CDP/Cux by Cathepsin L occurs during the G1/S-
phase transition and is coupled to cell cycle progression (Goulet
et al., 2004). Whether proteolytic processing of H3 is cell cycle
dependent remains unclear, although it is interesting to note
that our studies were done in ESCs, which cycle rapidly and
spend a high percentage of time in S-phase as measured by
flow cytometry (data not shown).
Third, and more broadly, does this proteolytic mechanism
apply to other histone substrates or to other cathepsin family
members or cathepsin-like proteases, and is the general mech-
anism conserved in other organisms or operating in other stages
of development or differentiation? Although Cathepsin L is the
only member of this family shown to localize to the nucleus,
the conservation in genomic structure and sequence between
this protease and its related family members suggest that other
cathepsins may function similarly.
Finally, with other mechanisms of histone demethylation well
documented (i.e., enzymatic demethylation, variant replace-
ment, etc.), does histone proteolysis serve other purposes that
are not appreciated, such as the generation of new N-termini?
Alternatively, histone cleavage may remove critical recognition
elements and thereby block the binding of downstream effectors
(see Figure 7D). Such questions will be the aims of future studies.
EXPERIMENTAL PROCEDURES
Cell Culture and Differentiation
ES cells (LF2 line, gift from Austin Smith) were cultured and differentiated with
RA as previously described (Bernstein et al., 2006b; Smith, 1991). For more
detail, see Supplemental Experimental Procedures.
Cellular Extract Preparation
Whole cell extracts were prepared by resuspending cell pellets in SDS-
Laemmli sample buffer and boiling immediately. Chromatin extracts were
prepared by sonicating chromatin pellets in buffer (10 mMHEPES, 10mMKCl,
1.5 mM MgCl2, 0.34M sucrose, 10% glycerol, 5 mM b-mercaptoethanol)
after isolation by various methods (Dignam et al., 1983; Mendez and Stillman,
2000). Digestion of chromatin fractions into mononucleosomes was accom-
plished by treatment with microccocal nuclease as described (Wysocka
et al., 2001). For more detail, see Supplemental Experimental Procedures.
Histone Purification and Mapping of H3 Cleavage Sites
Histones were acid extracted from nuclei and purified by RP-HPLC as de-
scribed (Shechter et al., 2007). H3 sub-bands were excised and subjected
to Edman degradation as described previously (Strahl et al., 1999) using a
Procise 492 cLC Sequencer from Applied Biosystems. Fraction 54 was
digested and analyzed by MS-MS as described in Supplemental Experimental
Procedures.
In Vitro H3 Cleavage Assay
Extracts were incubated in buffer (10 mM HEPES, 10 mM KCl, 1.5 mMMgCl2,
0.34M sucrose, 10%glycerol, 5 mM b-mercaptoethanol, all final) with 0.1 mg/ml
rH3-HIS (purified from E. coli), incubated at 37C for 1-3 hr, and analyzed
by immunoblotting with HIS-HRP and/or H3.cs1 antibody. For MS analysis,
reactions were quenched by addition of 0.1% (final) TFA. rCathepsin L (R&D
Systems 1515-CY-010), rCathepsin B (R&DSystemsBAF965), and rCathepsin
K (Calbiochem 342001) were purchased from commercial sources.
Enzyme Enrichment and Identification
3 days + RA differentiating ESC chromatin pellets were solubilized by sonica-
tion in buffer A (80 mM NaPO-4, 200 mM NaCl), injected onto a 2 or 5 ml hy-
droxyapatite column (BioRad), and fractionated with a 200 mM to 2M NaCl
gradient. Each fraction was then assayed as described above and subjected
to MS analysis (see Supplemental Experimental Procedures).
Antibodies
The following antibodies were purchased from commercial vendors: Cathep-
sin L (R&D Systems AF1515), Cathepsin B (R&D Systems AF965), Penta-HIS
HRP Conjugate Kit (QIAGEN 34460), Oct3/4 (BD Transduction Laboratories
611202), H3gen (Abcam 1791), H3K4me3 (Abcam 8580), H3K27me2 (Millipore
07-452). See Supplemental Experimental Procedures for details on the gener-
ation of the H3cs.1 and N-terminal H3gen antibodies.
Plasmid Construction and Recombinant Protein Purification
See Supplemental Experimental Procedures.
RNAi Knockdown
Short hairpins were purchased from Open Biosystems (RHS3979-9628371
and RMM3981-9597987) and transfected into 293T cells to produce Lentiviral
particles. Heterogeneous ESC lines were created by infection and selection
with puromycin.
Binding Assays
Peptide pull-down assays were performed as described (Wysocka, 2006) us-
ing biotinylated peptides conjugated to streptavidin agarose beads (Pierce20349). Elutions were loaded onto 10 or 15% SDS-PAGE gels and silver
stained. Fluorescence anisotropy was performed as described (Bernstein
et al., 2006b) using FAM-labeled peptides. For details on quantification, see
Supplemental Experimental Procedures.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, Supple-
mental References, and Seven Figures and can be foundwith this article online
at http://www.cell.com/supplemental/S0092-8674(08)01248-8.
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